LumiraDx’s Broad Menu of Lab Comparable Results on Single, Portable Diagnostic Platform Promises to Transform Community Care
|
By LabMedica International staff writers Posted on 13 Nov 2021 |
|
LumiraDx (London, UK) is offering a broad menu of lab comparable results on the LumiraDx Platform, its next generation point of care diagnostic system, that aims to transform community care.
The LumiraDx Platform combines a small, portable instrument, advanced low cost test strip and seamless secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform and tests are designed on the same principles as lab analyzer systems, to deliver accurate results compared to laboratory reference assays across a number of parameters, in a portable, easy-to-use point of care solution. The platform is designed to go wherever the patient is, whether this is in a hospital, medical office, pharmacy, or in other non-traditional settings such as schools or airports. Easy and intuitive to use, it requires only basic training and is designed to be affordable and accessible at the point of care. The company has a pipeline of more than 30 assays, initially focused on some of the most common conditions being diagnosed or managed with POC testing such as coagulation disorders, infectious diseases, cardiovascular and diabetes.
LumiraDx has developed SARS-CoV-2 antigen and antibody tests that provide lab comparable results for COVID-19 testing in minutes on a single platform. The LumiraDx SARS-CoV-2 Ag Test on the LumiraDx platform enables physicians to verify infection quickly, begin proper treatment and to initiate isolation precautions helping prevent further spread of infection. Similarly, the LumiraDx SARS-CoV-2 Ab Test is designed to be used in community care settings to identify individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The company also offers the SARS-CoV-2 Ag Surveillance Test for environments such as schools and workplaces that allows simultaneous testing of up to five samples on its platform with cost per sample as low as USD 4. With digital results in less than 12 minutes from sample application and a comprehensive connectivity solution, it is designed to measure population health metrics in real-time to help prevent the spread of infection using the LumiraDx affordable, easy-to-use, onsite testing platform.
The LumiraDx Platform menu also includes point of care tests for INR and D-Dimer with high levels of accuracy comparable to central lab-based tests. The LumiraDx INR Test measures prothrombin time reported as International Normalized Ratio (INR) from a single, direct fingerstick blood sample - all in less than 90 seconds. The LumiraDx D-Dimer Test is an easy to use fluorescence immunoassay designed to rapidly quantify D-Dimer levels in human whole blood and plasma at the point of care. It is the first quantitative micro-fluidic immunoassay of its kind, providing a precise and accurate D-Dimer result from a single direct fingerstick blood sample, in only six minutes. All point of care tests on the LumiraDx Platform menu have achieved CE Mark and are commercially available in Europe.
Related Links:
LumiraDx
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
Ovarian cancer is considered one of the deadliest cancers, in part because it rarely shows clear symptoms in its early stages, and diagnosis is often complex. Current approaches make it difficult to accurately... Read more
Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more
Molecular Diagnostics
view channel
Blood Test Could Detect Proteins Linked to Alzheimer's Disease and Memory Loss
Alzheimer’s disease has long been associated with sticky amyloid plaques in the brain, but these markers alone do not fully explain the memory loss and cognitive decline patients experience.... Read more
Brain Inflammation Biomarker Detects Alzheimer’s Years Before Symptoms Appear
Alzheimer’s disease affects millions globally, but patients are often diagnosed only after memory loss and other symptoms appear, when brain damage is already extensive. Detecting the disease much earlier... Read more
First-of-Its-Kind Blood Test Detects Over 50 Cancer Types
Many cancers lack routine screening, so patients are often diagnosed only after tumors grow and spread, when options are limited. A faster, less invasive approach that broadens early detection could shift... Read more
Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk
Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read moreImmunology
view channel
Novel Tool Uses Deep Learning for Precision Cancer Therapy
Nearly 50 new cancer therapies are approved each year, but selecting the right one for patients with highly individual tumor characteristics remains a major challenge. Physicians struggle to navigate the... Read more
Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more
Microbiology
view channel
Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Sepsis arises from infection and immune dysregulation, with neutrophils playing a central role in its progression. However, current clinical tools are unable to both isolate these cells and assess their... Read more
New Diagnostic Method Confirms Sepsis Infections Earlier
Sepsis remains one of the most dangerous medical emergencies, often progressing rapidly and becoming fatal without timely intervention. Each hour of delayed treatment in septic shock reduces patient survival... Read more
New Markers Could Predict Risk of Severe Chlamydia Infection
Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Portable Spectroscopy Rapidly and Noninvasively Detects Bacterial Species in Vaginal Fluid
Vaginal health depends on maintaining a balanced microbiome, particularly certain Lactobacillus species. Disruption of this balance, known as dysbiosis, can increase risks of infection, pregnancy complications,... Read morePathology
view channel
Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma
Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more
Clinicopathologic Study Supports Exclusion of Cervical Serous Carcinoma from WHO Classification
High-grade serous carcinoma is a rare diagnosis in cervical biopsies and can be difficult to distinguish from other tumor types. Cervical serous carcinoma is no longer recognized as a primary cervical... Read more
Technology
view channel
Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine
The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Rapid Diagnostic Technology Utilizes Breath Samples to Detect Lower Respiratory Tract Infections
Respiratory tract infections (LRTIs) are leading causes of illness and death worldwide, particularly among vulnerable populations such as the elderly, young children, and those with compromised immune systems.... Read more
Industry
view channel
VedaBio Partners With Mammoth Biosciences to Expand CRISPR-Based Diagnostic Technologies
VedaBio (San Diego, CA, USA) has entered into a non-exclusive license agreement with Mammoth Biosciences (Brisbane, CA, USA) for the use of select CRISPR-based technologies in diagnostic applications.... Read more
